首页> 外文期刊>Saudi Pharmaceutical Journal >Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis
【24h】

Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis

机译:肾移植合并肺结核和肺外结核患者的抗结核药物性肝炎

获取原文
           

摘要

Hepatotoxicity is a major side-effect of the medicines used in tuberculosis therapy. Although the guidelines for the management of antituberculosis drug induced hepatitis have been published from varieties of health institutes and organizations, they are to a great extent highly similar, there are nevertheless some important differences. We report a case of hepatitis in a renal transplant recipient admitted with pulmonary and extra pulmonary (abdominal) tuberculosis and review the literature on this topic. The introduction of antimicrobial teams, including specialist pharmacists, microbiologists and infectious disease physicians, is a major factor to improve the quality of care and faces the overcoming of antimicrobial resistance. Reintroducing one antituberculosis drug at a time with close monitoring of liver enzymes seems to be the optimal approach in the management of antituberculosis drug induced hepatitis. With multi-disciplinary clinical approach the patient has been successfully cured and has returned to normal active life.
机译:肝毒性是用于结核病治疗的药物的主要副作用。尽管各种医疗机构和组织已经发布了抗结核药物性肝炎的治疗指南,但它们在很大程度上相似,但仍存在一些重要差异。我们报告了一名接受肺和肺外(腹部)结核病移植的肾移植患者的肝炎病例,并回顾了有关该主题的文献。包括专业药剂师,微生物学家和传染病医师在内的抗菌团队的引入是提高护理质量并克服抗菌素耐药性的主要因素。一次重新引入一种抗结核药并密切监测肝酶,似乎是治疗抗结核药诱发的肝炎的最佳方法。通过多学科临床方法,患者已成功治愈,并恢复了正常的生活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号